Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)

Inclusion Criteria: 1. Patient had the symptoms of acute myocardial infarction within 12 hours with ST-segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB. 2. Male or female over 20 years of age 3. Signed written informed consent to participate in the study Exclusion Criteria: 1. Congestive heart failure (NYHA Class III or IV) or LVEF \<35%. 2. Clinically significant heart disease requiring CABG, cardiac transplantation, surgical repair and/or replacement during the course of the study. 3. Previous MI or CABG 4. Known serious or hypersensitivity reactions to statin, antiplatelet agents (aspirin or clopidogrel), or heparin. 5. Known familial hypercholesterolemia 6. Known skeletal muscle disease 7. Known active liver disease such as hepatitis or liver cirrhosis (except for fatty liver) 8. Renal failure (Cr \>2.0 mg/dL) 9. Secondary causes of hyperlipoproteinemia: uncontrolled primary hypothyroidism, and/or nephrotic syndrome 10. Non-cardiac comorbidity with a life expectation \< 1 year 11. Contraindications to CMRI (eg, implanted pacemaker or cardiac defibrillator, claustrophobia, etc.) 12. Pregnant or lactating women or women of childbearing potential 13. Participation in any investigational drug or device study within 30 days prior to study entry